Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 2nd Congress on Controversies in Multiple Myeloma (COMy) Congress will bring to the forefront the latest and most controversial data and information in the field of Multiple Myeloma, providing a unique opportunity for world class leaders in the field to debate vital and contentious issues in Myeloma. This thought-provoking academic dialogue will address the most challenging current clinical and therapeutic questions.

COMy 2016

28–30 April 2016 | Paris, France

COMy 2016

28–30 April 2016 | Paris, France

The 2nd Congress on Controversies in Multiple Myeloma (COMy) Congress will bring to the forefront the latest and most controversial data and information in the field of Multiple Myeloma, providing a unique opportunity for world class leaders in the field to debate vital and contentious issues in Myeloma. This thought-provoking academic dialogue will address the most challenging current clinical and therapeutic questions.

COMy 2016: Highlights from Day 1 18:18
COMy 2016: Highlights from Day 1
Arnon Nagler et al. • 29 Apr 2016
COMy 2016: new developments in multiple myeloma 4:39
COMy 2016: new developments in multiple myeloma
Thierry Facon • 29 Apr 2016
Frontline therapy for multiple myeloma 1:27
Frontline therapy for multiple myeloma
Antonio Palumbo • 30 Apr 2016
Renal complications in multiple myeloma – trials and next steps 1:36
Renal complications in multiple myeloma – trials and next steps
Nelson Leung • 29 Apr 2016
The pros and cons of MRI and PET-CT for assessing response in multiple myeloma 4:01
The pros and cons of MRI and PET-CT for assessing response in multiple myeloma
Evangelos Terpos • 30 Apr 2016
History of approvals for proteasome inhibitors bortezomib, carfilzomib and ixazomib 2:26
History of approvals for proteasome inhibitors bortezomib, carfilzomib and ixazomib
Michel Delforge • 29 Apr 2016
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma 3:22
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Hervé Avet-Loiseau • 30 Apr 2016
Definitions of smouldering myeloma and when to treat 1:38
Definitions of smouldering myeloma and when to treat
Antonio Palumbo • 29 Apr 2016
How to generate an anticancer immune response in multiple myeloma 3:04
How to generate an anticancer immune response in multiple myeloma
Paula Rodríguez-Otero • 29 Apr 2016
Why novel multiple myeloma drugs are expensive 6:17
Why novel multiple myeloma drugs are expensive
Jean-Luc Harousseau • 29 Apr 2016
Open questions in the use of imaging techniques for assessing response in multiple myeloma 1:40
Open questions in the use of imaging techniques for assessing response in multiple myeloma
Evangelos Terpos • 30 Apr 2016
Why it is crucial to assess response in multiple myeloma 1:32
Why it is crucial to assess response in multiple myeloma
Carlos Fernández De Larrea • 29 Apr 2016
Monoclonal antibodies and checkpoint inhibitors for multiple myeloma 1:40
Monoclonal antibodies and checkpoint inhibitors for multiple myeloma
Sagar Lonial • 30 Apr 2016
Assessment and treatment of smouldering myeloma 4:08
Assessment and treatment of smouldering myeloma
Maria-Victoria Mateos • 30 Apr 2016
How to diagnose smouldering myeloma 1:15
How to diagnose smouldering myeloma
Antonio Palumbo • 23 Apr 2016
Phase I trial results for nivolumab and pembrolizumab in lymphoma and multiple myeloma 3:09
Phase I trial results for nivolumab and pembrolizumab in lymphoma and multiple myeloma
Paula Rodríguez-Otero • 29 Apr 2016
The content of VJHemOnc is intended for healthcare professionals